Wells Fargo analyst Eva Fortea Verdejo has maintained their bullish stance on MRUS stock, giving a Buy rating today.
Eva Fortea Verdejo has given her Buy rating due to a combination of factors including the promising potential of Merus’s petosemtamab in treating head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (mCRC). The upcoming ASCO update is anticipated to provide crucial insights into the efficacy of petosemtamab in first-line HNSCC, with expectations of favorable progression-free survival (PFS) and overall survival (OS) trends.
Additionally, the company’s robust cash position, which is projected to support operations into 2028, strengthens its ability to advance ongoing studies and achieve key milestones. The anticipated updates in the second half of 2025 are expected to offer early efficacy insights for petosemtamab in mCRC, further supporting the stock’s potential. Despite a slight decrease in the price target due to increased R&D spending, the overall outlook remains positive, with the stock’s potential in HNSCC being well-recognized by the market.
Fortea Verdejo covers the Healthcare sector, focusing on stocks such as Xencor, Merus, and Arcus Biosciences. According to TipRanks, Fortea Verdejo has an average return of -1.7% and a 57.89% success rate on recommended stocks.